Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design Ezra Erives∗, Emilio Ferrara∗, Sean Michael, Nikhil Mallipeddi, Bowen Jing‡ ∗These authors contributed equally ‡Correspondence to: bowen@divergencelabs.com Abstract Food allergy affects an estimated 220–250 million people worldwide, for whom the constant risk of a severe reaction weighs heavily on quality of life. Allergic reactions are triggered by the cross-linking of allergen-specific IgE bound to its high-affinity receptor, FcεRI, on mast cells and basophils, causing degranulation, inflammation and, in severe cases, anaphylaxis. Omalizumab (Xolair), the sole FDA-approved biologic for food allergy, neutralizes circulating IgE; however, it does not effectively remove IgE from FcεRI, where it can persist for weeks and where even a small residual amount can sustain sensitivity. Here we describe an agentic computational design campaign with Claude toward a disruptive inhibitor antibody that physically removes bound IgE from FcεRI.
Guided by our research team, Claude pursued a biparatopic molecule that pairs a disruptor arm, which displaces IgE from FcεRI, with a non-competing anchor arm that holds the molecule on receptor-bound IgE. Of 91 experimentally characterized disruptor designs, 20 showed activity against receptor-bound IgE by competitive bio-layer interferometry, and in a dose-titration assay three variants removed more IgE than omalizumab at therapeutically relevant concentrations (25–400 nM). De novo designs for the anchor arm bound IgE at diverse epitopes with apparent affinities of 3.4–235 nM. These subcomponents provide the starting point for further characterization toward a best-in-class IgE disruptor. 1 Introduction Food allergy is an atopic disease characterized by the overproduction of IgE reactive against otherwise harmless environmental or food antigens.
Allergen-induced cross-linking of IgE bound to the high-affinity receptor FcεRI of mast cells and basophils releases preformed and newly synthesized inflammatory medi- ators, resulting in classical symptoms ranging from moderate urticaria to severe, fatal anaphylaxis (Fig- ure 2b) [1]. In the United States the disease affects up to 8% of children and about 10% of adults, roughly 33 million people in all, with about 40% of affected children reactive to more than one food [2–4]. Until re- cently, the only option for food allergy patients was strict allergen avoidance and self-injectable epinephrine for accidental exposures [5]. The fundamental pathway of food allergy is the interaction of allergen-specific IgE with the high-affinity receptor FcεRI of mast cells and basophils, one of the strongest protein-receptor interactions in human immunology.
IgE binds FcεRIα with an affinity near 10−10 M and dissociates so slowly that mast cells and basophils stay fully sensitized whether or not allergen is present [6–8], supported by continuous IgE production by B cells [9–11]. While free IgE has a serum half-life of about two days, receptor-bound IgE persists in human skin for weeks to months [9, 12–14]. Additionally, mast cells and basophils are exquisitely sensitive to IgE cross-linking. For reference, a basophil carries some 105 FcεRI, yet only a few thousand allergen-specific IgE molecules, one or two per cent of the receptor pool, give a half-maximal response, and only a few hundred are enough to initiate secretion [15–17].
Therefore, food allergen 1 a Therapeutic thesis & mechanism Disruptor arm opens Cε3 Anchor arm binds receptor-bound IgE IgE leaves, no cross-linking To design: disruptor arm anchor arm b Claude-orchestrated design campaign Objective decomposition & strategy literature · mechanism · modeling tools · phase plan Disruptor redesign design, critics, filtering 11,273 designs → 91 nominated De novo anchor design design, critics, filtering 23,600 designs → 57 nominated Claude-executed Claude-steered, human in the loop c Kinetics characterization Competitive BLI (disruptor arm) IgE bound IgE + disruptor buffer omalizumab disruptor 20 out of 91 VHHs removed IgE, 3 faster than omalizumab. Standard BLI (anchor arm) response time 3 of 57 de novo anchors bound IgE, KD = 3.4, 32.5 and 235 nM. d Toward a therapeutic biparatopic anchor disruptor biparatopic NHP cross-reactivity humanness developability cellular function & anaphylactogenicity · · · in vivo Figure 1. Overview of biparatopic disruptive IgE inhibitor design campaign. (a) We sought to design a biparatopic VHH whose anchor arm binds receptor-bound IgE and whose disruptor arm forces IgE into a non-FcεRIα-competent state, so that it departs the receptor without cross-linking (from Figure 2d). (b) The design campaign, simplified from Figure 3. Claude decomposed the objective with human input and ran both design phases. (c) Characterization by bio-layer interferometry: competitive BLI for the disruptor arm and standard BLI for the anchor arm. (d) Judicious pairing of the two arms via geometric analysis will provide the starting point for further in vitro and in vivo characterization toward a therapeutic biparatopic. reactivity is the result of a baseline state of fully sensitized and highly reactive mast cells and basophils driven by continuous allergen-specific IgE production by B cells.
Over the past decade, the management and treatment of food allergy have been revolutionized. Most no- tably, in 2024 omalizumab (Xolair), a humanized anti-IgE antibody, became the first FDA-approved medi- cation to reduce allergic reactions to multiple foods [5, 18, 19]. In the OUtMATCH trial, 16 to 20 weeks of omalizumab allowed 67% of patients with multi-food allergy to tolerate 600 mg of peanut protein, against 7% on placebo [18]. This is a major advance for the treatment of food allergy, yet it is far from completely addressing the disease.
Only 42% of treated patients completed the full 6,044 mg cumulative challenge for two of their foods and 24% for all three. Furthermore, 14% could not consume even 30 mg of peanut after the full 16 to 20 weeks of treatment [18]. The treatment regimen is also burdensome. Because omalizumab neutralizes IgE stoichiometrically, the dose is set by body weight and total IgE.
Patients must take 75 to 600 mg of drug by injection every two or four weeks, with no established dosing for patients whose body weight and/or total IgE lie outside the approved label, excluding a significant population. Furthermore, because omalizumab does not alter IgE production, free IgE returns after discontinuation of drug, requiring patients to be treated indefinitely [5, 19]. Omalizumab therefore protects against accidental exposure, but patients are advised to continue avoiding their allergens and must carry epinephrine [5, 19]. Omalizumab nonetheless represents a breakthrough in the treatment of food allergy and validates IgE as the central mediator of the disease.
Its limitations derive from the biology of the IgE:FcεRIα interaction and from the development goals set for omalizumab in the 1990s (Figure 2) [20, 21]. 2 a IgE Fc geometry and conformational heterogeneity Closed Cε3: free, bent IgE-Fc FcεRI site shut; CD23 site open Cε3 Cε3 Cε4 Cε4 Cε2 pair (behind) 37.1 Å Open Cε3: receptor-bound FcεRIα D2 straddles both Cε3 Cε2 pair Cε3 Cε3 Cε4 Cε4 D1 D2 FcεRIα 41.6 Å b FcεRI-bound IgE and cross-linking mast cell / basophil D2 D1 D2 D1 Sensitized, resting IgE stays on FcεRI for weeks no allergen, no signal D2 D1 D2 D1 allergen Allergen cross-links two IgE receptors cluster; the cell degranulates within minutes activation degranulation c Omalizumab: inhibition vs disruption Neutralizes free IgE epitope on Cε3 overlaps the FcεRI site omalizumab KD ≈ 0.2 nMfree IgE cannot load the receptor bound IgE untouched Disrupts bound IgE only at high concentration omalizumab-derived scFv on the partially disrupted complex Cε3 Cε4 Cε4 D2 D1 FcεRIα levered D2 rotated 14°, shifted 5 Å omalizumab-derived scFv in the opened sub-site second copy levers the receptor d Biparatopic disruption mechanism Cε3 Cε3 Cε4 Cε4 Cε2 FcεRIα leaves disruptor arm opening Cε3 sub-site anchor arm non-competing epitope on the IgE-Fc (same camera as a) arm sites are placeholders 1 anchor arm binds receptor-bound IgE 2 disruptor arm enters the opening Cε3 site 3 IgE leaves with the VHH; no cross-linking on the cell Facilitated dissociation Cε2 Cε3 Cε3 Cε4 Cε4 D1 D2 Cε2 Cε3 Cε3 Cε4 Cε4 D1 D2 Cε2 Cε3 Cε3 Cε4 Cε4 D1 D2 scFv scFv Cε2 Cε3 Cε3 Cε4 Cε4 D1 D2 scFv scFv sub-site 1 sub-site 2 sub-site 1 opens and recloses antibody binds the exposed site receptor lets go intact complex both sub-sites held transient opening site 1 exposed, site 2 holds antibody in the opened site a second copy levers site 2 IgE captured in a non-binding state receptor free an antibody that engages the transiently exposed interface traps IgE and prevents re-binding orange: receptor-contact residues of sub-sites 1 and 2; states 2–4 from the trapped intermediate, state 1 from the native complex e Cε2 Cε3 Cε4 IgE Fab (V light, C mid) FcεRIα omalizumab (V light, C dark) anchor arm disruptor arm allergen membrane receptor sub-site 1 receptor sub-site 2Figure 2. IgE biology and the disruption problem. (a) IgE-Fc conformations. Free IgE-Fc (PDB 2WQR) is bent, with the Cε2 pair folded back and the Cε3 domains closed; receptor-bound IgE-Fc (PDB 1F6A) has the Cε3 domains open, straddled by FcεRIα D2. Cε3 center-to-center distances are marked; the Cε2 pair on the right is from PDB 7SHT (dashed). (b) Allergen-induced clustering of IgE:FcεRI on an effector cell activates the cell and releases granule mediators. (c) Omalizumab binds free IgE on Cε3 and blocks receptor loading, but its epitope is covered on receptor-bound IgE.
Right, a partially disrupted complex (PDB 7SHT). (d) Biparatopic disruptor concept. An anchor arm (blue) binds a non-overlapping epitope and holds the molecule on receptor-bound IgE; a disruptor arm (green) enters the Cε3 site as it opens and levers the receptor off. Arm positions are illustrative (E3_53 and E2_79 sites, PDB 7MXI). Caption continues on the next page. 3 Figure 2.
IgE biology and the disruption problem (continued). (e) Facilitated dissociation of IgE:FcεRIα complex by omalizumab, and antibody variants derived from omalizumab. The IgE:FcεRIα complex opens transiently at one of its two Cε3 sub-sites (orange; sub-site 1 light, sub-site 2 dark) while the other holds; an antibody that binds the exposed site blocks re-engagement, the second sub-site releases, and IgE leaves bound to the antibody in a non-binding state. State 1, native complex (PDB 1F6A, Cε2 pair from 7SHT); states 2–4, the trapped disruption intermediate (PDB 7SHT) with an omalizumab-derived scFv in the opened sub-site 1 and a second copy levering FcεRIα at sub-site 2 (14◦, 5 Å), shown without the an- tibody (2) and without the receptor (4). Structures superposed on the Cε4 pair, one camera; domains drawn as heavy-atom outlines.
IgE exists in two forms, free in the circulation and bound to FcεRI on the cell surface, and at therapeutically relevant doses omalizumab neutralizes only the free form (Figure 2c). Because IgE triggers reactions through clustering of the bound form, neutralizing free IgE disarms the cell only as fast as its existing complexes turn over: basophils lose most of their surface IgE within about ten days, but FcεRI-positive mast cells in skin are unchanged after one week and reduced only after ten [22–24]. The medicine with the greatest potential for patients with food allergy would therefore not only neutralize free IgE but also remove the IgE already bound to effector cells (Figure 2). 2 Neutralizing and disruptive IgE inhibitors Omalizumab neutralizes free IgE by binding to the IgE Cε3 chain at two symmetrically related epitopes, and in a manner which both directly overlaps with the bound conformation of FcεRIα, and which additionally prevents the folded-back conformation of the Cε2-domain believed to stabilize the IgE:FcεRIα
Texto de divergencelabs.com tal como lo publicó, leído de su página y mostrado aquí con el formato de El Autómata. El original, en divergencelabs.com · Volver a la noticia de El Autómata